Pryor Cashman represented CytoDel, Inc. in connection with a private placement of Series A Convertible Preferred Stock to institutional accredited investors, led by a leading private equity fund that invests in significant scientific discoveries and supports them by providing capital and expertise. The offering closed on January 5, 2018.
Tamed botulinum toxin ferries miniature antibodies into nerves to reverse paralysis
New York City, January 6, 2021 – CytoDel, Inc. (“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found here.